European guidelines for quality assurance in colorectal cancer screening and diagnosis. – First Edition Faecal occult blood testing

Halloran, Stephen P; Launoy, Guy; Zappa, Marco

doi:10.1055/s-0032-1309791

Cited by 94 publications

(132 citation statements)

References 117 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Each article covers one of the 10 chapters of the guidelines [3,[16][17][18][19][20][21][22][23][24], the annex of the chapter dealing with quality assurance in pathology [25], the section on principles of evidence assessment and methods for reaching recommendations [28], or the executive summary [26]. The results section of each chapter article begins with a list of key recommendations with a dual grading showing the strength of each recommendation and the supporting evidence.…”

Section: Author Manuscript Author Manuscriptmentioning

confidence: 99%

“…The fourth chapter includes 21 detailed recommendations concerning the design, application and selection of appropriate FOBTs in CRC screening [18]. The ideal biochemical test for population screening of CRC would use a biomarker, specific and sensitive for cancer and advanced pre-cancer, with an easily collected sample that could be safely and cheaply transported to a centralized laboratory for accurate, reproducible and inexpensive automated analysis.…”

Section: Faecal Occult Blood Testingmentioning

confidence: 99%

“…Comprehensive European quality assurance guidelines for breast and cervical cancer screening have been developed by experts and published by the EU [14,15]. The new European guidelines for quality assurance in colorectal cancer screening and diagnosis [3,[16][17][18][19][20][21][22][23][24][25][26][27]] make similar principles, standards and recommendations available to healthcare professionals, scientists, decision-makers and other stakeholders seeking to establish or improve CRC screening programmes.The content of the evidence-based multidisciplinary guidelines is presented in 13 articles in a recent Supplement to Endoscopy. Each article covers one of the 10 chapters of the guidelines [3,[16][17][18][19][20][21][22][23][24], the annex of the chapter dealing with quality assurance in pathology [25], the section on principles of evidence assessment and methods for reaching recommendations [28], or the executive summary [26].…”

mentioning

confidence: 99%

“…The new European guidelines for quality assurance in colorectal cancer screening and diagnosis [3,[16][17][18][19][20][21][22][23][24][25][26][27]] make similar principles, standards and recommendations available to healthcare professionals, scientists, decision-makers and other stakeholders seeking to establish or improve CRC screening programmes.…”

mentioning

confidence: 99%

See 3 more Smart Citations

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

Karsa¹,

Patnick²,

Segnan³

et al. 2012

Endoscopy

251

187

View full text Add to dashboard Cite

Population-based screening for early detection and treatment of colorectal cancer (CRC) and precursor lesions, using evidence-based methods, can be effective in populations with a significant burden of the disease provided the services are of high quality. Multidisciplinary, evidence-based guidelines for quality assurance in CRC screening and diagnosis have been developed by experts in a project co-financed by the European Union. The 450-page guidelines were published in book format by the European Commission in 2010.They include 10 chapters and over 250 recommendations, individually graded according to the strength of the recommendation and the supporting evidence. Adoption of the recommendations can improve and maintain the quality and effectiveness of an entire screening process, including identification and invitation of the target population, diagnosis and management of the disease and appropriate surveillance in people with detected lesions. To make the principles, recommendations and standards in the guidelines known to a wider professional and scientific community and to facilitate their use in the scientific literature, the original content is presented in journal format in an open-access Supplement of Endoscopy. The editors have prepared the present overview to inform readers of the comprehensive scope and content of the guidelines. IntroductionAccording to recent estimates by the International Agency for Research on Cancer [1], colorectal cancer (CRC) is the most common cancer in Europe with 432 000 new cases reported annually in men and women combined. It is the second most common cause of cancer deaths in Europe with 212 000 deaths reported in 2008.Worldwide, CRC ranks third in incidence and fourth in mortality with an estimated 1.2 million cases and 0.6 million deaths annually. In the 27 Member States of the European Union (EU), CRC ranks first in incidence and second in mortality, with approximately 334000 new cases and 149000 deaths estimated in 2008.Even in those Member States in the lower range for age-standardized rates of CRC, the burden of disease is significantly greater when compared with many other HHS Public Access Author Manuscript Author ManuscriptAuthor ManuscriptAuthor Manuscript regions of the world (see reference [1]). CRC is therefore an important health problem across the EU.Screening can be effective in cancer control in populations with a significant burden of CRC, provided the services are of high quality [2]. The aim of CRC screening is to lower the burden of cancer in the population by discovering disease in its early, latent stages [3]. Evidence-based methods permit treatment that is more effective than if disease is diagnosed later when symptoms have occurred. Early treatment of invasive lesions, for example by endoscopic resection of early CRC, can also be less detrimental for quality of life. The endoscopic removal of pre-malignant lesions also reduces the incidence of CRC by avoiding the progression to cancer. Randomized trials in people of average risk invite...

show abstract

Section: Author Manuscript Author Manuscriptmentioning

confidence: 99%

Section: Faecal Occult Blood Testingmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

Karsa¹,

Patnick²,

Segnan³

et al. 2012

Endoscopy

251

187

View full text Add to dashboard Cite

show abstract

“…Chapter 4 [11] includes 21 detailed and in some cases complex recommendations dealing with design and application of faecal occult blood tests in CRC screening. It is recognised that the ideal biochemical test for population-screening of colorectal cancer would use a biomarker, specific and sensitive for both cancer and pre-cancer, on an easily collected sample, that could be safely and cheaply transported to a centralised laboratory for accurate, reproducible, and inexpensive automated analysis.…”

Section: Chapter 4 -Faecal Occult Blood Testingmentioning

confidence: 99%

Untitled

2012

Endoscopy

View full text Add to dashboard Cite

show abstract

Recommendations for a step‐wise comparative approach to the evaluation of new screening tests for colorectal cancer

Young

Senore

Mandel

et al. 2016

Cancer

View full text Add to dashboard Cite

BACKGROUNDNew screening tests for colorectal cancer continue to emerge, but the evidence needed to justify their adoption in screening programs remains uncertain.METHODSA review of the literature and a consensus approach by experts was undertaken to provide practical guidance on how to compare new screening tests with proven screening tests.RESULTSFindings and recommendations from the review included the following: Adoption of a new screening test requires evidence of effectiveness relative to a proven comparator test. Clinical accuracy supported by programmatic population evaluation in the screening context on an intention‐to‐screen basis, including acceptability, is essential. Cancer‐specific mortality is not essential as an endpoint provided that the mortality benefit of the comparator has been demonstrated and that the biologic basis of detection is similar. Effectiveness of the guaiac‐based fecal occult blood test provides the minimum standard to be achieved by a new test. A 4‐phase evaluation is recommended. An initial retrospective evaluation in cancer cases and controls (Phase 1) is followed by a prospective evaluation of performance across the continuum of neoplastic lesions (Phase 2). Phase 3 follows the demonstration of adequate accuracy in these 2 prescreening phases and addresses programmatic outcomes at 1 screening round on an intention‐to‐screen basis. Phase 4 involves more comprehensive evaluation of ongoing screening over multiple rounds. Key information is provided from the following parameters: the test positivity rate in a screening population, the true‐positive and false‐positive rates, and the number needed to colonoscope to detect a target lesion.CONCLUSIONSNew screening tests can be evaluated efficiently by this stepwise comparative approach. Cancer 2016;122:826–39. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

show abstract

European guidelines for quality assurance in colorectal cancer screening and diagnosis. – First Edition Faecal occult blood testing

Abstract: • " mass screening • " colorectal neoplasms • " stool test • " laboratory quality control • " quality assessment • " multidisciplinary evidencebased guidelines • " population-based programmes Bibliography

Cited by 94 publications

References 117 publications

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

Untitled

Recommendations for a step‐wise comparative approach to the evaluation of new screening tests for colorectal cancer

Contact Info

Product

Resources

About